Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Labs

It doesn't get any safer for income investors than Dividend Kings.

Want Safe and Growing Passive Income? Buy These 2 Dividend Kings In 2023

Gilead Sciences

Vertex Pharmaceuticals

Their products will enjoy strong demand regardless of what happens with the economy.

3 Smart Stocks to Buy if a Recession Is on the Way

AbbVie

My main thesis is to explain why AbbVie Inc. remains my top 2023 dividend stock in the healthcare space despite its near-record stock prices. The thesis is best illustrated by comparison and contrast against another dividend champ, Johnson & Johnson.

Better 2023 Dividend Stock: AbbVie Or Johnson & Johnson?

Verizon

In late morning trading Friday, the Dow Jones industrial average traded up 0.27%, the S&P 500 up 0.71% and the Nasdaq up 1.16%.

Earnings Previews: Johnson & Johnson, 3M, Verizon

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.

J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector

Mastercard

Occidental Petroleum

These top-notch Buffett stocks are no-brainer buys right now.

3 No-Brainer Warren Buffett Stocks to Load Up On for 2023

Target

These stocks can add safety and growth to your portfolio.

3 Top Passive-Income Stocks to Own in 2023

Alphabet

Microsoft

Last year was rough for the stock market, but that doesn't mean that all stocks should be avoided. Many names have fallen sharply over the last 18 months, and that has given investors an opportunity to focus on blue-chip stocks that have excellent, long-term outlooks.

3 Safe Stock Bets for an Unpredictable Market

J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.

J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study

Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

Johnson & Johnson (NYSE:JNJ)'s wholly-owned pharmaceutical company Janssen Pharmaceuticals and its global research partners have discontinued their Phase 3 Mosaico study of Janssen's investigational human immunodeficiency virus (HIV) vaccine after it was found not effective in preventing infections. The company said in a statement that no safety issues with the vaccine regimen were identified.

J&J discontinues HIV trial in latest setback to vaccine pursuit

Chevron

Danaher

NextEra Energy

Tesla

Visa

The fourth quarter earnings season is always the most important because it reveals the full year performance of the companies as well.

10 Biggest Companies Reporting Earnings in the 4th Week of Jan 2023

NEW BRUNSWICK, N.J.--( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ) will participate in the SVB Securities Global Biopharma Conference on Wednesday, February 15th. Biljana Naumovic, Worldwide Vice President, Oncology and Peter Lebowitz, Global Therapeutic Head, Oncology will represent the Company in a virtual session scheduled at 1:00 p.m. (Eastern Time).

Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference

Johnson & Johnson's JNJ, -1.17% experimental HIV vaccine is safe but not effective, and the late-stage study will be discontinued as a result of that finding, federal researchers said Wednesday. J&J's stock was down 1.1% in trading on Wednesday afternoon.

J&J's HIV vaccine fails Phase 3 clinical trial

Amgen

Boeing

General Dynamics

Kimberly-Clark

Kenvue

L3Harris

Lockheed Martin

Altria

Merck

Northrop Grumman

Philip Morris

Raytheon Technologies

Investing in blue-chip companies that pay dividends and relentlessly focusing on reinvesting the proceeds is a proven strategy for reliable long-term returns. But what about the occasional black swan? Potentially devastating litigation? Overlooked liabilities on the balance sheet? Financial engineering?

Blue-Chip Stocks And Red Flags - Things To Consider In Your Due Diligence

The company will likely see a steady rise in revenue led by continued market share gains for its drugs - Darzalex, Stelara, Erleada, and Tremfya.

What To Expect From Johnson & Johnson's Q4?

I'm aiming to grow my passive income this year through adding these safe value stocks to my portfolio that have strong dividend yields.

3 Dividend Stocks For Passive Income

Amazon

Coca-Cola

McKesson

Procter & Gamble

These stocks deliver a lot of the elements Buffett loves most.

5 Warren Buffett Stocks to Buy Hand Over Fist in 2023

We believe that pharmaceutical giants Johnson & Johnson stock (NYSE: JNJ) and Merck stock (NYSE: MRK) will likely offer similar returns over the next three years.

Pick Either Johnson & Johnson Stock Or Its Peer – Both May Offer Similar Returns

Disney

Among the Dow Jones Industrial Average's 30 components, there are two jaw-dropping deals and one overachiever worth avoiding.

2 Dow Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague

Realty Income Corp

With economic uncertainty ahead, many investors will be looking for the best dividend investment opportunities for 2023. Here are the top performers so far.

The 5 Best-Performing Dividend Stocks In 2023?

A partnership with rival Merck & Co. to help make the shots, forged at the urging of the U.S. government, hasn't lived up to expectations. The companies are now engaged in arbitration.

J&J slashes production of its unpopular COVID-19 shot

After mobilizing to quickly develop and manufacture a Covid-19 vaccine, Johnson & Johnson has vastly scaled back its efforts in producing the shots as it faces slumping demand

News for Johnson & Johnson Stock (JNJ)